We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

UNITY Biotechnology Inc (UBX) USD0.0001

Sell:$1.50 Buy:$1.51 Change: $0.005 (0.33%)
NASDAQ:2.05%
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$1.50
Buy:$1.51
Change: $0.005 (0.33%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$1.50
Buy:$1.51
Change: $0.005 (0.33%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.

Contact details

Address:
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 4161192
Website:
https://unitybiotechnology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
UBX
ISIN:
US91381U2006
Market cap:
$25.26 million
Shares in issue:
16.79 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Keith Leonard
    Chairman of the Board
  • Anirvan Ghosh
    Chief Executive Officer, Director
  • Lynne Sullivan
    Chief Financial Officer, Head of Corporate Development
  • Alexander Nguyen
    General Counsel and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.